Core Insights - Eli Lilly's shares surged after the company reported second-quarter earnings that exceeded expectations, driven by strong demand for its weight-loss drugs and updates on production capacity [1] Demand for Weight-Loss Drugs Fuels Growth - Sales of Mounjaro, a weight-loss drug, increased over threefold year-over-year to $3.09 billion in the quarter - Zepbound, another weight-loss drug, achieved sales of $1 billion within less than a year of FDA approval in November 2023 - CEO David Ricks noted that U.S. demand for both drugs is strong and growing, with improvements in supply and access [2] Supply Chain Developments - Eli Lilly has invested approximately $18 billion since 2020 in building and upgrading manufacturing facilities in the U.S. and Europe - A significant project includes a $5.3 billion investment in an Indiana facility aimed at producing ingredients for Zepbound and Mounjaro, bringing total investment in that facility to $9 billion - Interim CFO Gordon Brooks mentioned that the company has reached several supply-related milestones, enhancing clarity on production expansion, although high demand may still lead to periodic supply tightness [3] Clinical Trials and Additional Benefits - Recent trials indicate that Zepbound may offer benefits beyond weight loss, such as reducing the risk of severe cardiovascular incidents and alleviating sleep apnea severity - Eli Lilly plans to submit clinical trial findings on Zepbound's cardiovascular impact to the FDA and other regulators within the year, and has already submitted an application for Zepbound to be prescribed for sleep apnea treatment, with an FDA decision expected by the end of 2024 [4] Alzheimer's Drug Approval - Eli Lilly received FDA approval for Kisunla, a monthly IV infusion drug that has shown potential in slowing Alzheimer's progression in clinical trials - The company expressed satisfaction with the early prescription of Kisunla since its approval, noting that it is broadly covered for Medicare patients - Following these developments, Eli Lilly's shares rose nearly 10% to $845.31, contributing to a 45% gain since the beginning of the year [5]

Financial Performance - Revenue grew 36% in Q2 2024, with new products contributing nearly $3.5 billion compared to the same period last year [8][16] - Excluding the sale of rights to Baqsimi last year, revenue growth was 46% [16] - Gross margin increased from 79.8% in Q2 2023 to 82% in Q2 2024, benefiting from favorable product mix and higher realized prices [16] - Operating income increased by 90% in Q2, driven by higher revenue from new products [17] - Earnings per share reached $3.92, an 86% increase compared to the prior year [17] Business Line Performance - Mounjaro sales in Q2 were $3.1 billion globally, with $2.4 billion in the U.S. [22] - Zepbound achieved sales of over $1.2 billion in Q2, with approximately 86% access in the commercial segment [23] - Trulicity revenue declined 31% globally, primarily due to competitive dynamics and supply constraints [22] - Verzenio sales increased 44% worldwide, driven by the early breast cancer indication [21] Market Performance - U.S. revenue increased 42% in Q2, with volume growth of 27% driven by Zepbound, Mounjaro, and Verzenio [17] - Revenue in Europe grew 20% in constant currency, primarily driven by Mounjaro uptake [20] - Japan saw a 15% revenue growth in constant currency, with volume growth of 21% [20] - Revenue in China increased 1% in constant currency, driven by Olumiant and Taltz [20] Company Strategy and Industry Competition - The company is focused on expanding its manufacturing capabilities, with a $5.3 billion investment in Indiana [12] - Lilly aims to comprehensively address obesity with 11 new molecules in clinical trials across multiple indications [10] - The company is well-positioned to compete in the obesity market, with significant access for Mounjaro and Zepbound [55] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting momentum to accelerate through the year [8] - The company anticipates production of salable doses of incretin medicines in the second half of 2024 to be at least 1.5 times that of the first half [24] - Management highlighted the importance of expanding access to Zepbound and improving supply chain dynamics [19] Other Important Information - The company announced the FDA approval of Kisunla for Alzheimer's disease and positive results from the tirzepatide heart failure trial [27][29] - Management noted the resignation of the CFO and the appointment of an interim CFO [14][15] Q&A Session Summary Question: Average Selling Price Movements - The company noted stable pricing across quarters in 2024, with initial favorability driven by Mounjaro [44][46] Question: Manufacturing Guidance - Management reiterated that the 1.5-fold increase in sellable doses includes the new Zepbound vials, with production ramping up [48][49] Question: Competition in Obesity Market - Management emphasized barriers to entry for new competitors and highlighted the company's strong market position with multiple Phase 3 assets [52][54] Question: Compounded GLP-1s - The company is monitoring the impact of compounded formulations on patient health and is considering legal actions against mass production practices [60][61] Question: Operating Leverage - Management discussed expectations for operating margins to remain in the upper 30% range, with promotional spending increasing in the second half of the year [64][68] Question: International Sales for Incretins - The company reported strong progress with Mounjaro's launch outside the U.S., achieving leading market shares in early launch countries [70][72] Question: NASH Development - The company is working on developing non-invasive biomarkers for NASH trials and is excited about the potential of tirzepatide in this indication [76][78]

Core Insights - Eli Lilly reported a 36% increase in revenue, primarily driven by Mounjaro, Zepbound, and Verzenio, with EPS rising 68% year-on-year, surpassing analysts' estimates by 42% [1] - The company raised its full-year revenue guidance by $3 billion and highlighted significant progress in its drug pipeline, including approvals for Kisunla and Jaypirca, and positive clinical trial results for tirzepatide [1] Financial Performance - Eli Lilly's current market cap stands at $535 billion, with a potential to reach $1 trillion if the stock price doubles [3] - The GLP-1 market is projected to grow over 20% annually, reaching $133 billion by 2030, with Eli Lilly holding a dominant position due to Mounjaro [3] - Revenue is expected to grow by 23% this year, and if the company maintains a 20% growth rate, it could reach $100 billion in three to four years [4] Growth Projections - Analysts estimate Eli Lilly's EPS to grow at an annual rate of 33.3% over the next three to five years, indicating strong growth potential [5] - Current sales estimates for Eli Lilly show a projected revenue of $42.99 billion for the current year and $53.05 billion for the next year, with year-over-year growth estimates of 25.97% and 23.41% respectively [8] Competitive Landscape - Eli Lilly's competitors, Novo Nordisk and Hims & Hers Health, are also experiencing significant growth, with Novo Nordisk reporting a 24% increase in sales and Hims & Hers Health achieving a 52% year-on-year revenue increase [6][7] - The GLP-1 market trend is substantial, and while Eli Lilly is a strong candidate for investment, competitors also present appealing opportunities [11]

Core Viewpoint - Eli Lilly reported a significant earnings beat, with a stock price increase of 8.3% following the announcement of Q2 results, raising questions about the sustainability of its high P/E ratio of 54.5 [1][3]. Financial Performance - Eli Lilly's Q2 earnings per share were reported at $3.92, significantly higher than the expected $2.60, with total sales reaching $11.3 billion compared to the forecast of $9.9 billion [1][2]. - The company experienced a 36% growth in quarterly sales and a 68% increase in profits year-over-year [2]. Key Products Driving Growth - The growth was primarily driven by the success of its GLP-1 drugs, Mounjaro and Zepbound, with Mounjaro sales tripling to $3.1 billion, accounting for over 27% of total sales, while Zepbound generated $1.2 billion in sales, representing more than 10% of total sales [2]. - Verzenio, a cancer drug, also contributed to growth with a 44% increase in sales [2]. Future Outlook - Management has raised its full-year sales forecast to approximately $46 billion, largely due to the strong performance of Mounjaro and Zepbound, with an expected earnings per share of $15.35 [3]. - Analysts predict that while current growth rates are high, they may decline to about 35% annually in the long term, raising concerns about the sustainability of the stock's high valuation [3].

Core Viewpoint - Eli Lilly and Company reported strong second-quarter 2024 results, with adjusted earnings per share of $3.92, significantly surpassing the Zacks Consensus Estimate of $2.64, and an 86% year-over-year increase in earnings [1] - Revenues reached $11.3 billion, a 36% year-over-year increase, also exceeding the Zacks Consensus Estimate of $9.83 billion [1] Revenue Breakdown - Key growth products generated $5.05 billion, a 3% increase, while new products contributed $4.46 billion, led by Mounjaro and Zepbound [2] - Mounjaro sales were $3.09 billion, up from $1.81 billion in the previous quarter, exceeding the Zacks Consensus Estimate of $2.34 billion [2][3] - Zepbound recorded sales of $1.24 billion, significantly higher than $517.4 million in the previous quarter and beating the model estimate of $700 million [3] Market Performance - U.S. revenues increased by 42% to $7.84 billion, while international revenues rose by 25% to $3.47 billion [2] - Net realized prices increased by 10%, and volumes rose by 27% in the reported quarter [2] Competitive Landscape - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products, which also saw significant sales growth [4] - Novo Nordisk's GLP-1 diabetes sales increased by 32% at constant exchange rates, with Ozempic and Wegovy sales rising by 30% and 53%, respectively [4] Guidance Update - The company raised its 2024 revenue guidance to a range of $45.4 billion to $46.6 billion, up from $42.4 billion to $43.6 billion, and increased earnings per share guidance to $16.10 to $16.60 [7] - Strong demand for Mounjaro and Zepbound, along with non-incretin products, contributed to the upward revision of guidance [9] Stock Performance - Following the strong results and guidance increase, Eli Lilly's shares surged by 13% in pre-market trading [9] - The stock has risen 32.5% year-to-date, outperforming the industry average increase of 14.7% [9] Recent Developments - The FDA approved donanemab, branded as Kisunla, for treating early symptomatic Alzheimer's disease, which is expected to generate significant sales [10] - Eli Lilly announced the acquisition of Morphic Therapeutics for approximately $3.2 billion, aimed at expanding its immunology pipeline [11]

PART I. Financial Information [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated condensed financial statements for the three and six months ended June 30, 2024, including statements of operations, comprehensive income, balance sheets, shareholders' equity, and cash flows, with detailed notes on accounting policies and events [Consolidated Condensed Statements of Operations](index=5&type=section&id=Consolidated%20Condensed%20Statements%20of%20Operations) The company reported significant growth in revenue and net income for the three and six months ended June 30, 2024, compared to the same periods in 2023, with Q2 revenue increasing **36%** to **$11.3 billion** and net income rising **68%** to **$3.0 billion**, resulting in a diluted EPS of **$3.28** Q2 & H1 2024 Financial Performance (YoY) | Financial Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | YoY Change | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $11,302.8 M | $8,312.1 M | +36.0% | $20,070.8 M | $15,272.1 M | +31.4% | | **Net Income** | $2,967.0 M | $1,763.2 M | +68.3% | $5,209.9 M | $3,108.1 M | +67.6% | | **Diluted EPS** | $3.28 | $1.95 | +68.2% | $5.76 | $3.44 | +67.4% | [Consolidated Condensed Balance Sheets](index=7&type=section&id=Consolidated%20Condensed%20Balance%20Sheets) As of June 30, 2024, total assets increased to **$71.9 billion** from **$64.0 billion** at year-end 2023, driven by growth in accounts receivable and property and equipment, while total liabilities grew to **$58.2 billion** and total equity rose to **$13.6 billion** Balance Sheet Summary | Account | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total Current Assets** | $30,204.3 M | $25,727.0 M | | **Total Assets** | $71,874.8 M | $64,006.3 M | | **Total Current Liabilities** | $27,121.2 M | $27,293.2 M | | **Long-term Debt** | $23,730.4 M | $18,320.8 M | | **Total Liabilities** | $58,239.3 M | $53,142.6 M | | **Total Equity** | $13,635.5 M | $10,863.7 M | [Consolidated Condensed Statements of Cash Flows](index=10&type=section&id=Consolidated%20Condensed%20Statements%20of%20Cash%20Flows) For the first six months of 2024, net cash provided by operating activities was **$2.6 billion**, net cash used for investing activities was **$3.4 billion**, and net cash provided by financing activities was **$1.2 billion** Cash Flow Summary (Six Months Ended June 30) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | **Net Cash Provided by Operating Activities** | $2,632.2 M | $2,362.5 M | | **Net Cash Used for Investing Activities** | ($3,376.3 M) | ($1,147.9 M) | | **Net Cash Provided by (Used for) Financing Activities** | $1,244.2 M | ($621.1 M) | | **Net increase in cash and cash equivalents** | $405.0 M | $627.5 M | [Notes to Consolidated Condensed Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Condensed%20Financial%20Statements) The notes provide detailed disclosures on key financial items, including revenue growth driven by Mounjaro, Zepbound, and Verzenio, a **$924.7 million** manufacturing facility acquisition, an agreement to acquire Morphic Holding for approximately **$3.2 billion**, and a **$435.0 million** charge for anticipated litigation payments - Total revenue for Q2 2024 was **$11.3 billion**, with net product revenue comprising **$10.4 billion** and collaboration/other revenue at **$0.9 billion**[32](index=32&type=chunk) - In May 2024, the company acquired a manufacturing facility in Wisconsin for **$924.7 million** to expand its injectable product manufacturing network[44](index=44&type=chunk) - In July 2024, the company announced an agreement to acquire Morphic Holding, Inc. for approximately **$3.2 billion**[51](index=51&type=chunk) - A charge of **$435.0 million** was recognized in Q2 2024 related to anticipated litigation payments[63](index=63&type=chunk) [Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Results%20of%20Operations%20and%20Financial%20Condition) Management discusses the key drivers of financial performance, highlighting a **36%** revenue increase in Q2 2024 led by Mounjaro, Zepbound, and Verzenio, along with late-stage pipeline developments, external factors like the Inflation Reduction Act, and significant investments in manufacturing capacity [Executive Overview](index=35&type=section&id=Executive%20Overview) The company's revenue grew **36%** in Q2 2024, driven by volume and price increases, primarily from Mounjaro, Zepbound, and Verzenio, with key pipeline developments including the U.S. approval of Donanemab for Alzheimer's, ongoing management of supply constraints for incretin medicines, and anticipated impacts from the Inflation Reduction Act - Q2 2024 revenue growth was driven by increased sales of Mounjaro, Zepbound, and Verzenio, partially offset by declines in Trulicity and the 2023 sale of Baqsimi rights[126](index=126&type=chunk) - Donanemab (Kisunla™) was approved in the U.S. in 2024 for early Alzheimer's disease[130](index=130&type=chunk) - Demand for incretin medicines has exceeded production, leading to periodic supply tightness, with the company expanding manufacturing capacity, and increases continuing in 2024 and beyond[136](index=136&type=chunk) - The Inflation Reduction Act (IRA) is expected to create pricing pressure, with Jardiance, part of a collaboration, selected for government-set prices effective in 2026[134](index=134&type=chunk) [Results of Operations](index=41&type=section&id=Results%20of%20Operations) Revenue for Q2 2024 increased **36%** to **$11.3 billion**, with U.S. revenue up **42%** and international revenue up **25%**, driven by a **27%** increase in volume and a **10%** increase in price, primarily from Mounjaro and Zepbound, while gross margin improved to **80.8%** and operating expenses rose due to continued investment Q2 2024 Revenue Growth Drivers (vs. Q2 2023) | Region | Volume | Price | Foreign Exchange | Total Change | | :--- | :--- | :--- | :--- | :--- | | **U.S.** | +27% | +15% | 0% | +42% | | **Outside U.S.** | +27% | 0% | -3% | +25% | | **Consolidated** | +27% | +10% | -1% | +36% | Top Product Revenue (Q2 2024) | Product | Q2 2024 Revenue | Q2 2023 Revenue | YoY Change | | :--- | :--- | :--- | :--- | | **Mounjaro** | $3,090.8 M | $979.7 M | +215% | | **Verzenio** | $1,331.9 M | $926.8 M | +44% | | **Trulicity** | $1,245.6 M | $1,812.5 M | -31% | | **Zepbound** | $1,243.2 M | $0 M | N/A | - Gross margin as a percent of revenue increased by **2.5 percentage points** to **80.8%** in Q2 2024, driven by higher realized prices and favorable product mix[150](index=150&type=chunk)[151](index=151&type=chunk) [Financial Condition and Liquidity](index=45&type=section&id=Financial%20Condition%20and%20Liquidity) The company's cash and cash equivalents increased to **$3.22 billion** at June 30, 2024, total debt rose to **$28.89 billion** following a **$6.50 billion** note issuance, significant capital expenditures are planned for manufacturing expansion, and a **$3.2 billion** acquisition of Morphic Holding, Inc. is pending, with **$2.50 billion** remaining under the share repurchase program - Total debt increased by **$3.67 billion** to **$28.89 billion** as of June 30, 2024, following a **$6.50 billion** debt issuance[154](index=154&type=chunk) - The company is making significant investments to expand manufacturing capacity and has entered into supply agreements that could require payments up to approximately **$10 billion** over several years[154](index=154&type=chunk) - Announced an agreement to acquire Morphic Holding, Inc. for approximately **$3.2 billion** in cash[154](index=154&type=chunk) - As of June 30, 2024, **$2.50 billion** remained under the authorized share repurchase program, with no shares repurchased during the first half of 2024[154](index=154&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=47&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section refers to the company's Annual Report on Form 10-K for the year ended December 31, 2023, for a detailed discussion of market risk - The company's disclosures about market risk are consistent with those in its 2023 Annual Report on Form 10-K[161](index=161&type=chunk) [Item 4. Controls and Procedures](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and interim CFO, evaluated the company's disclosure controls and procedures as of June 30, 2024, and concluded that they were effective, with no material changes made to the internal control over financial reporting during the second quarter of 2024 - The company's management concluded that disclosure controls and procedures were effective as of June 30, 2024[162](index=162&type=chunk) - There were no material changes in internal control over financial reporting during the second quarter of 2024[162](index=162&type=chunk) PART II. Other Information [Item 1. Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 10 of the consolidated condensed financial statements for detailed information on various legal actions, government investigations, and environmental proceedings involving the company - For information on legal proceedings, the report directs readers to Note 10 of the financial statements and the 2023 Annual Report on Form 10-K[164](index=164&type=chunk) [Item 1A. Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) The company states that there have been no material changes from the risk factors previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023 - No material changes to the risk factors disclosed in the 2023 Annual Report on Form 10-K have occurred[165](index=165&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=48&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company did not repurchase any of its equity securities during the three months ended June 30, 2024, with approximately **$2.5 billion** remaining available under the share repurchase program authorized in May 2021 Share Repurchase Activity (Q2 2024) | Period | Total Shares Purchased | Average Price Paid | Value Remaining in Program | | :--- | :--- | :--- | :--- | | **April 2024** | 0 | $0 | $2,500.0 M | | **May 2024** | 0 | $0 | $2,500.0 M | | **June 2024** | 0 | $0 | $2,500.0 M | [Item 5. Other Information](index=48&type=section&id=Item%205.%20Other%20Information) The company reports that none of its directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the second quarter of 2024 - No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements in Q2 2024[168](index=168&type=chunk) [Item 6. Exhibits](index=49&type=section&id=Item%206.%20Exhibits) This section lists the documents filed as exhibits with the Quarterly Report, including certifications by the CEO and interim CFO, and interactive data files

Core Insights - Eli Lilly and Co. reported second-quarter earnings that exceeded Wall Street expectations, driven by strong sales of its weight-loss drugs Mounjaro, Zepbound, and Verzenio [1] - The company raised its full-year revenue outlook by $3 billion, now projecting between $45.4 billion and $46.6 billion [1] Financial Performance - Eli Lilly achieved global revenue of $11.3 billion in the second quarter, surpassing the expected $9.92 billion [1] - Adjusted earnings per share were reported at $3.92, exceeding Wall Street's estimate of $2.60 [1] Product Sales - Mounjaro's global revenue reached $3.09 billion, a significant increase from $979.7 million in the same quarter last year [2] - U.S. revenue for Mounjaro was $2.41 billion, up from $915.7 million year-over-year [2] - Zepbound, launched in November 2023, generated $1.24 billion in U.S. revenue [2] Market Outlook - The weight-loss drug sector is projected to reach $105 billion by 2030, with potential growth up to $144 billion according to Morgan Stanley [3] - Despite a recent forecast reduction from Novo Nordisk regarding its weight-loss drug Wegovy, Eli Lilly plans to increase supply of its own weight-loss medications [3]

Core Insights - Eli Lilly reported $11.3 billion in revenue for Q2 2024, a 36% year-over-year increase, with an EPS of $3.92 compared to $2.11 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $9.83 billion by 14.99%, and the EPS surpassed the consensus estimate of $2.64 by 48.48% [1] Revenue Performance - Net Sales for Cyramza (Ramucirumab) in the US were $116.10 million, slightly below the average estimate of $119.78 million, marking a 1% year-over-year increase [3] - International Net Sales for Humalog were $196.90 million, slightly below the estimate of $198.53 million, reflecting a 6.5% year-over-year decline [4] - International Net Sales for Forteo were $38.50 million, below the estimate of $42.90 million, showing a significant 23.9% year-over-year decline [5] - International Net Sales for Alimta were $21.40 million, compared to the estimated $28.12 million, representing a 50.4% year-over-year decline [6] - Total Net Sales for Cyramza were $248.90 million, slightly below the estimate of $252.22 million, indicating a 4.4% year-over-year decline [7] - Net Sales for Humulin were $223.60 million, exceeding the estimate of $184.50 million, with an 8.9% year-over-year increase [8] - Net Sales for Humalog reached $631.60 million, significantly above the estimate of $383.68 million, reflecting a 43.4% year-over-year increase [9] - Net Sales for Forteo were $69.90 million, below the estimate of $107.27 million, showing a 52.8% year-over-year decline [11] - Net Sales for Erbitux were $155.80 million, slightly below the estimate of $162.77 million, indicating a 4.1% year-over-year decline [12] - Net Sales for Alimta were $33.90 million, compared to the estimate of $37.38 million, representing a 44.3% year-over-year decline [13] - Net Sales in Oncology reached $2.16 billion, exceeding the estimate of $2.04 billion, with a 29.2% year-over-year increase [14] - Net Sales in Neurosciences were $339.50 million, above the estimate of $287.50 million, reflecting a 12.3% year-over-year decline [15] Stock Performance - Shares of Eli Lilly have returned -17.8% over the past month, compared to the Zacks S&P 500 composite's -6.5% change [15] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [15]

Group 1 - Eli Lilly's stock increased by 13% after exceeding analyst expectations and raising its guidance, driven by strong performance from its GLP-1 drugs, Zepbound and Mounjaro [1] - The company reported a net income of $2.97 billion, or $3.28 per share, on revenue of $11.3 billion, and raised its full-year revenue guidance to $45.4 billion-$46.6 billion and earnings per share guidance to $15.10-$15.40 [1] - The market reacted positively, with shares trading over $874 and a market capitalization exceeding $825 billion [1] Group 2 - Lilly resolved its two-year-long shortages of diabetes drugs, with seven production sites operational by the end of Q1 [2] - Mounjaro generated $3.1 billion in sales in Q2, while Zepbound brought in over $1.2 billion, compensating for declining sales of older medications like Trulicity [2] - The success of GLP-1 drugs has enhanced the visibility of other Lilly products, such as Jardiance and Verzenio [2] Group 3 - The competitive landscape includes Pfizer, Amgen, and Viking Therapeutics, which are developing similar drugs, while Novo Nordisk remains a primary competitor with its offerings [3] - The current market dynamics suggest that GLP-1 drugs could be transformative for diabetes and obesity treatment, akin to the impact of statins in the 1990s [3]

Eli Lilly (LLY) came out with quarterly earnings of $3.92 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 48.48%. A quarter ago, it was expected that this drugmaker would post earnings of $2.53 per share when it actually produced earnings of $2.58, delivering a surprise of 1.98%.Over the last four quarters, the company has su ...